All in all, the above results all supported that biological processes related to HEY2-based ceRNA regulatory network, tumor immunosuppressive environment, cell stemness, and IDH1 mutation may be involved in the progression and treatment of glioma. Here, HEY2 is linked to central nervous system cancer.